Skip to content

Effect of treatment on miRNA levels on OCD

A Study to assess alteration in plasma levels of miRNA-132 and miRNA-134 after treatment in patients with obsessive-compulsive disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/04/041628
Enrollment
50
Registered
2022-04-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F429- Obsessive-compulsive disorder, unspecified

Interventions

Control Intervention1: NIL: NIL

Sponsors

Medical Research Unit
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i. Meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) presented by the American Psychiatric Association (Washington, D.C., USA) ii. Aged between 16 and 50 years old iii. A YaleBrown Obsessive-Compulsive Scale (Y-BOCS) score >16 points; for simple obsessive or forced behavior, a Y-BOCS score >8 points. iv. No other major mental illnesses. v. No history of psychiatric drug use. vi. Give written informed consent.

Exclusion criteria

Exclusion criteria: i. A history of organic brain disease or serious physical illness, symptoms of psychosis, or a history of other mental illnesses ii. Severe depression (a Hamilton Depression Rating Scale (HAMD) score >35 points) iii. Second-generation with a family history of mental illness.

Design outcomes

Primary

MeasureTime frame
1. To assess alteration in plasma levels of miRNA-132 in patients with obsessive-compulsive disorder before and after treatment 2. To assess alteration in plasma levels of miRNA-134 in patients with obsessive-compulsive disorder before and after treatmentTimepoint: 24 weeks

Secondary

MeasureTime frame
1. To find correlation between levels of miRNA-132 and clinical indicators before and after treatment. 2. To find correlation between levels of miRNA-134 and clinical indicators before and after treatment.Timepoint: 24 weeks

Countries

India

Contacts

Public ContactDr Amit Jain

Guru Gobind Singh Medical College

dramitjain@ggsmch.org9417319980

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026